Media Articles Related to Edluar (Zolpidem)
Tips to Avoid Insomnia
Source: MedicineNet Sleep Specialty [2016.06.24]
Title: Tips to Avoid Insomnia
Created: 12/10/2008 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM
Menopausal Insomnia: CBT May Offer Robust, Long-term Relief
Source: Medscape NeurologyHeadlines [2016.06.22]
Cognitive behavioral therapy and sleep restriction therapy both ease insomnia symptoms and fatigue in menopausal women. However, CBT-I may be superior.
Medscape Medical News
Could less time in bed prevent chronic insomnia?
Source: Psychology / Psychiatry News From Medical News Today [2016.06.14]
New research suggests people with acute insomnia may be able to prevent it developing into chronic insomnia by spending less - not more - time in bed.
Study shows strong prevalence of insomnia symptoms among female veterans
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2016.06.10]
Over 47% of female veterans reported insomnia symptoms.A new study sheds light on the prevalence of insomnia symptoms among female veterans.
Insomnia Quiz: Test Your Sleep Hygiene IQ
Source: MedicineNet Sleep Aids And Stimulants Specialty [2016.06.07]
Title: Insomnia Quiz: Test Your Sleep Hygiene IQ
Category: MedicineNet Quiz
Created: 6/6/2016 12:00:00 AM
Last Editorial Review: 6/7/2016 2:46:56 PM
Published Studies Related to Edluar (Zolpidem)
Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in
primary insomnia in comparison to zolpidem: a randomized controlled trial. 
insomnia... CONCLUSIONS: NSF-3 is a safe and effective short-term alternative to zolpidem for
Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset
following spontaneous middle-of-the-night awakening in insomnia in a randomized,
double-blind, placebo-controlled, outpatient study. 
to sleep after MOTN awakenings... CONCLUSIONS: 3.5 mg ZST used as needed significantly reduced latency to return to
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
CONCLUSIONS: Zolpidem extended-release administered concomitantly with escitalopram for up to 24 weeks was well tolerated and improved insomnia and some sleep-related next-day symptoms and next-day functioning in patients with MDD but did not significantly augment the antidepressant response of escitalopram. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00296179. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
The use of a non-benzodiazepine hypnotic sleep-aid (Zolpidem) in patients undergoing ACL reconstruction: a randomized controlled clinical trial. [2011.05]
PURPOSE: Previous studies have addressed post-operative pain management after ACL reconstruction by examining the use of intra-articular analgesia and/or modification of anesthesia techniques. To our knowledge, however, no previous studies have evaluated the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction. The purpose of this prospective, blinded, randomized, controlled clinical study was to evaluate the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction... CONCLUSION: Adding zolpidem to the post-operative medication regimen after arthroscopic ACL reconstruction helps to lower the amount of narcotic pain medication required for adequate analgesia. LEVEL OF EVIDENCE: Randomized controlled clinical trial, Level I.
Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. [2011.04]
RATIONALE: Although hypnotics are primarily used by older people, the residual effects the morning after a single nighttime intake of the two most commonly prescribed hypnotics, zolpidem (Zp) and zopiclone (Zc), on older middle-aged drivers have not been evaluated and compared... CONCLUSIONS: This is the first study revealing residual effects of Zp on driving performance in ageing drivers which are similar to that of Zc. Studying the effects of medication in different age ranges appears useful to complete the studies on behavioural-pharmacological effects of medication. To reduce the incidence of driving accidents due to prescription drugs, patients should be warned at the time of treatment initiation that they should avoid driving.